Business Wire

DEGIRO Retailises European Online Brokerage With Zero Commission Trading on Top US and European Exchanges

18.11.2021 17:38:00 EET | Business Wire | Press release

Share

Today, flatexDEGIRO (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe's largest and fastest-growing pan-European retail online broker announced the introduction of zero commission trading at DEGIRO, starting as of 22 November 2021. DEGIRO customers across Europe will thereby be able to trade without any commission over 5,000 US equities directly on the leading US exchanges NASDAQ and NYSE. Additionally, in the most important growth markets, France, Spain, Portugal and Italy, as well as in Sweden and Denmark, they will trade all ETFs commission-free as well as equities on the respective local Tier 1 exchanges, including Euronext Paris, and Lisbon, NASDAQ Stockholm, Bolsa de Madrid and Borsa Italia.

For the very first time, European retail investors will be able to trade at zero commission without having to compromise on quality, service, security, product choice or place of execution. flatexDEGIRO leverages its technological edge, its financial strengths and the scale of its market-leading pan-European online brokerage business to make this unique offer. The attractiveness and quality of the offer is expected to lead to an increasing revenue base and additional economies of scale which, together with optimised monetisation, should strongly improve flatexDEGIRO's operating profitability.

Frank Niehage, CEO of flatexDEGIRO: "With 'DEGIRO goes zero', we are changing the face of online brokerage in Europe. DEGIRO provides the lowest prices in the market with full cost transparency and no compromise on quality. We are now not only leading in platform and product but also in price. This will further increase the attractiveness of long-term investing and trading on our platform for millions of Europeans. No one interested in online brokerage should ever again feel the need to trade with brokers who supposedly charge no commissions but offer only intransparent and low-quality alternatives."

Muhamad Chahrour, CEO of DEGIRO and CFO of flatexDEGIRO: "It's as simple as that: for years, many so-called 'neo-brokers' claimed to offer zero commission trading - but at what costs? Clients were attracted to trade either highly risky CFDs or with market makers having intransparent product-pricing and scrutinised payments for order flow. No retail customer should ever again accept this specious trade-off. We promised to retailise capital market access - this is exactly what we now do with this revolutionary step. DEGIRO launches the first fair and most transparent zero commission retail brokerage, not relying on any payment for order flow."

Complex variable fee structures for external cost such as exchange fees and regulatory costs will be eliminated by a transparent and simple flat handling fee of as little as 50 Cents per transaction. DEGIRO also supports the best access to international equity markets with transparent and outstanding FX services and fees, including one of the lowest FX fees in the whole financial industry of just 0.25%.

About flatexDEGIRO AG

flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates one of the leading and fastest growing online brokerage businesses in Europe, executing millions of paperless securities transactions per annum. B2C customers in 18 European countries are serviced via the flatex and DEGIRO brands and offered a wide range of independent products at competitive pricing, based on a modern, in-house state-of-the-art technology.

With more than 1.25 million customers and over 75 million securities transactions in 2020, flatexDEGIRO is the largest retail online broker in Europe. In a time of bank consolidation, low interest rates and digitalization, the flatexDEGIRO Group is ideally positioned for further growth. Within the next five years, flatexDEGIRO aims to grow its customer base to 7-8 million customers, settling 250-350 million transactions per year - even in years with low volatility.

More information via https://www.flatexdegiro.com/en

Language:

English

Company:

flatexDEGIRO AG

Rotfeder-Ring 7

60327 Frankfurt / Main

Germany

Phone:

+49 (0) 69 450001 0

E-mail:

ir@flatexdegiro.com

Internet:

www.flatexdegiro.com

ISIN:

DE000FTG1111

WKN:

FTG111

Indices:

SDAX

Listed:

Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1250311

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Achim Schreck Tel. +49 (0) 69 450001 0
Head of IR & Corporate Communications achim.schreck@flatexdegiro.com
flatexDEGIRO AG
Rotfeder-Ring 7
D-60327 Frankfurt/Main

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Angel Aligner Unveils Six Innovations for 202711.11.2026 18:23:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bindu Saran, VP of Product Strategy, added: “Angel was founded by orthodontic profe

Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 16:58:00 EET | Press release

Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gathering of Future Health – A Global Initiative by Abu Dhabi, curated and convened by the Department of Health – Abu Dhabi (DoH) together with Founding Partners PureHealth, M42, Institute for Healthier Living Abu Dhabi (IHLAD) and Mubadala Bio. Held from 20–22 October, the Summit attracted more than 17,300 visitors from 85 countries. It brought together health leaders, researchers, policymakers, investors and inn

De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 16:58:00 EET | Press release

The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par

Starr Chile Assigned A Rating from AM Best11.11.2026 15:30:00 EET | Press release

Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr

Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 15:22:00 EET | Press release

Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an outcome. End customers for Epinal’s SEB include breathalyzer manufacturers, healthcare, mobile computers & clinical smartphones, handheld bio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye